Search

Catherine Demers Recombinent human growth hormone has achieved clinical responses when used for treating heart failure. Catherine Demers of McMaster University told the American Heart Association conf

Anthony Keech Among nearly 10 000 patients with maturity onset diabetes the use of fenofibrate to lower cholesterol produced a 24 per cent statistically significant reduction of cardiovascular events,

Judith Hochman from New York University told Audio Medica that patients taking aspirin need to take it half an hour before any NSAID in order to avoid drug interactions, and had these comments about t

Gunnar Gislason As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other no

Frans van der Werf Near-complete data from the ASSENT-4-PCI trial investigating facilitated PCI (combining both thrombolysis and primary PCI after acute myocardial infarction) has found that PCI alone

Olivier Bertrand The use of abciximab perfusion after stenting was questioned at the American Heart Association meeting in Dallas. The EASY study found bolus administration of glycoprotein 2B3A inhibi

Milton Packer In the REVIVE trial the inotropic agent levosimendan has improved short-term outcome in acutely decompensated heart failure. Milton Packer from the University of Texas. [audio:https://ww

Gordon Tomaselli Gordon Tomaselli commented on Milton Packer’s findings at the Dallas meeting of the American Heart Association. [audio:https://www.audiomedica.com/podcasting/aha2005/Gordon_Toma

Bryan Williams Bryan Williams, University of Leicester Measuring blood pressure with a cuff around the arm does not always give a clear picture of what’s happening in the aorta. The CAFE study f

Volker Schächinger Regeneration of the heart has been achieved by using bone-marrow derived stem cells after myocardial infarction among 200 patients. Volker Schächinger, University of Frankfurt. [a

Gordon Tomaselli Gordon Tomaselli, Johns Hopkins School of Medicine Gordon Tomaselli commented on Volker Schächinger’s findings at the Dallas meeting of the American Heart Association. [audio:h

Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding